key: cord-0742461-9xyq3jkn
authors: Hunter, Philip
title: Lessons from COVID‐19: The ongoing pandemic has inspired and advanced research and development across a wide range of fields
date: 2021-09-17
journal: EMBO Rep
DOI: 10.15252/embr.202153834
sha: a50b8e9213cd068d4c5a9e9ee6f700c6862a2b2e
doc_id: 742461
cord_uid: 9xyq3jkn

From immunology to manufacturing to social science: COVID‐19 has been a boon for research and development in many research areas.[Image: see text]

T he COVID-19 pandemic has enabled an unprecedented mega-study of vaccine platforms, technologies, deployment strategies and publicity campaigns, with success determined not just by efficacy but also stubborn resistance to jabs. Many of the lessons have been positive, with a number of vaccines developed faster and performing far better than even optimists had dared to hope in January 2020. The pandemic also established for the first time that mRNA vaccines are both safe and effective, in fact, more so than many had expected.

Above all, it has left the world better prepared for the next pandemic. "We've learnt that it's possible to develop a vaccine quickly-the prediction is that it will take 100 days from when another pandemic starts", said Luke O'Neill at Trinity College, Dublin, Ireland. He also noted accumulating evidence that COVID-19 vaccines in general elicit longer lasting immunity than had been expected from experience of other coronaviruses that cause common colds. First results came from follow-up studies on patients who had recovered from COVID-19 infection by the start of 2021. One such study assessed 188 human cases spanning the full range of symptoms and analysed data on key immune markers, including SARS-CoV-2 memory B cells, CD8 + T cells, and CD4 + T cells more than 6 months after infection. The study noted a high degree of heterogeneity in the magnitude of adaptive immune responses; nonetheless, immune memory in three compartments remained measurable in more than 90% of subjects for more than 5 months after infection. The authors concluded that durable immunity against secondary COVID-19 disease was achievable for most people, despite significant individual variation. More recent studies have followed up with vaccinated individuals. A preprint manuscript described vaccine-specific CD4 + T cell, CD8 + T cell, binding antibody and neutralizing antibody responses to the Moderna mRNA vaccine over 7 months post-immunization at half the dose recommended for mass vaccination programmes (preprint: Mateus et al, 2021) . Even at this lower dose and after just a single shot, the authors observed durable Spike binding antibodies comparable to that of convalescent COVID-19 cases. Spike CD8 + T cells were generated in 88% of subjects, with equivalent percentages of CD8 + T cell memory responders.

Another finding from the same study is that prior exposure to related viruses led to increased CD4 + T cell and antibody responses to the vaccine. This builds on earlier studies reporting that a significant number of people have cross-reactive T cells that can specifically recognize a SARS-CoV-2 epitope, as well as the homologous epitope from one of the four common cold coronaviruses in circulation. It suggests that prior exposure to these coronaviruses conferred some immunity against COVID-19, although further experiments are needed to conform this. There is also evidence that prior exposure to Sars-CoV-2 itself amplifies the protective effect of subsequent vaccination. "That is one reason why people who have had natural infection should get vaccinated", said Alessandro Sette at the LaJolla Institute for Immunology in the USA and coauthor on the earlier study on durability of natural immunity to COVID-19 in February 2021. "This gives hybrid immunity, which is much better even than vaccine only".

According to Wolfgang Leitner, section head for innate immunity and adjuvants at the NIH, one of the best decisions made early on was to pursue multiple vaccine platforms as part of a diverse strategy. "With COVID-19, the US decided to invest in parallel in multiple technologies, both in RNA, protein and recombinant virus platforms", said Leitner, who added that it was impossible at that stage to tell which of the platforms would deliver, especially as mRNA vaccines had yet to be proven at scale. The wisdom of this shotgun approach has been confirmed by several high-profile successes and failures. Leitner added that no expert was confident a vaccine would be ready for full release anywhere near as quickly as actually happened. He admitted he had been pessimistic himself, partly because of experience with the original SARS-1 virus in 2003, when vaccines using the common adjuvant of an aluminium salt failed in the field. "They actually made the disease worst, because they induced the wrong type of immune response, leading to vaccine enhancement of disease", Leitner explained.

But lessons had been headed, although as Leitner pointed out, there is recognition that the world has got lucky. One reason is that COVID-19 was an easier target for vaccination while proving less severe than had been feared, according to John Moore, an immunologist at Weill Cornell Medical College, New York, USA. "Fortunately, Sars-CoV-2 is relatively simple to vaccinate against", he said. "It was clear fairly early on from phase 1 trials that these vaccines were producing respectable titres of neutralizing antibodies, the principal correlates of protection. Then again, this could have been a much worse virus. MERS killed about 30% of the people it infected, while Sars-CoV-1 had a fatality rate of 10%". Given the potential for a more serious pandemic caused by another coronavirus, influenza, or some unknown agent, one key implication for Moore is that virology research should be boosted to match up with vaccination programmes.

A unique aspect of the pandemic has been the opportunity to assess several different vaccine platforms and learn from the experience. Yet, Leitner cautions that it would be wrong to put all eggs in one basket when the pandemic experience has suggested that diversity increases chances of success. "It's the biggest vaccination experiment in history", he said. "But we need to be really careful about drawing conclusions for all diseases, because we are only looking at one. It would be wrong to say RNA is the platform because it has least side effects and best efficacy maybe for Sars-CoV-2. The jury is still out for other diseases". In fact, at least four principal platforms have been tried, with some yet to be properly assessed because they have taken longer to progress through clinical trials.

DNA vaccines are the oldest technology, involving administration of DNA plasmids encoding for one or more proteins from the target pathogen. In the case of COVID-19, they have taken longer to develop than others, but one called ZyCoV-D, developed by Indian pharmaceutical company Zydus Cadila, was submitted in India for emergency use authorization in July 2021. If approved, it will be the world's first DNA vaccine against Sars-CoV-2 with some advantages, such as being easily adaptable to new mutations and longer storage periods at normal fridge temperatures. The mRNA approach, in particular popularized by Pfizer and Moderna, delivers active mRNA encapsulated in lipid nanoparticles for protection against degradation before delivery into the cell. Although mRNA vaccine research dates back at least 10 years, it is only during the pandemic that it has been scaled up for phase III trials and subsequent large-scale production. This has demonstrated some of the advantages of the platform, namely high potency, low-cost manufacture and rapid development. RNA vaccines were the first to be approved for use in the EU, the USA and the UK.

Their biggest drawback has been the requirement for very low temperature storage. For this reason, efforts are continuing to stabilize the mRNA payload further to allow longer term storage at normal fridge temperatures. Some progress has already been made: in May 2021, the UK extended the period the Pfizer/BioNTech vaccine could be kept at fridge temperatures from 5 to 31 days, after reviewing the company's latest stability data.

Then, there are the viral vector vaccines, namely Oxford-AstraZeneca's AZD1222 and Russia's Sputnik, which use a modified version of the chimpanzee adenovirus ChAdOx1 to deliver the vaccine's genetic payload. This has proved safe and effective, but it has decreasing potency against the more transmissible forms of the virus, first the Alpha and then Delta variants. Its major disadvantage is increasing immunity against the chimp virus which could affect efficacy of the second dose, at least for AZD1222. Some countries therefore now recommend a second shot with a RNA-based vaccine to circumvent the issue. "There is a huge benefit mixing the Pfizer and the Astra Zeneca vaccine", said Kingston Mills of the Trinity Biomedical Sciences Institute in Dublin. "There is a 10-fold boost in antibody levels when the mRNA vaccine is given second after an initial Astra Zeneca shot". The main benefit, as Mills added, was that countries that have bought significant amounts of vaccines of both types can optimize the efficacy by mixing them.

Finally, there are protein vaccines, which have been slower to come. They directly employ recombinant versions of the COVID-19 spike protein, or at least components of it, in combination with an adjuvant. The most celebrated example is the Novavax vaccine, which in mid-2020 showed some of the highest titres of neutralizing antibodies but took much longer to ramp up for manufacturing. Almost a year later, in June 2021, Novavax finally showed good efficacy from a Phase 3 clinical trial involving 29,960 adult volunteers in the USA and Mexico, demonstrating 90.4% efficacy in preventing symptomatic COVID-19 disease. But the vaccine has come too late to play a role in the current combat against the pandemic. "I think they over-engineered it", commented Moore, who was enthusiastic about the vaccine's potential. "They could have made a simpler version just as good".

A second protein vaccine candidate is emerging through collaboration between Sanofi and GSK, which, to some surprise, initially stayed out of the COVID-19 vaccine race. But the companies then moved forward and claimed in May 2021 a strong immune response across all adult age groups in phase 2 trials. Pending positive phase 3 outcomes and regulatory reviews, the vaccine is on course for approval towards the end of 2021.

The immediate priority though is to ensure better preparedness for future pandemics and that vaccines will progress from design to delivery even faster next time. The US Operation Warp Speed deserves a lot of credit for laying the groundwork. "Operation Warp Speed certainly found ways to get rigorous science done more quickly", Moore commented. "No one is suggesting rigour over safety was dropped, but there was a realization we couldn't have the most draconian regulations affecting ability to get an actual vaccine developed at the time of real need. It was all hands to the pump". The compromise lay particularly in interleaving various steps that were previously taken one at a time. "We would do animal, phase one, then phase two in a linear way before. Now everything was done on overlapped timeline, so we could shorten the process considerably", Moore explained. The other big difference was committing to development and scaling up multiple vaccines in advance without knowing which would make it through the trials. Normally no pharmaceutical company would be willing to invest on that basis, so it was important governments stepped in and underwrote the risk. "In both the USA and Europe, the vaccines were pre-purchased", Moore said. "Because it was prefunded, companies could begin large-scale manufacture risk free". There were also lessons relating to the manufacturing process itself, according to Sarah Gilbert, who co-developed the Oxford-AstraZeneca vaccine with the Oxford Vaccine Group. "The stand-out lesson for me is that we need flexible vaccine manufacturing facilities available to respond", she said. "We can't conduct clinical trials unless we can manufacture the vaccine to GMP [Good Manufacturing Practice], and for phase III trials we need a lot of doses".

Another important lesson was the societal response, in particular resistance to vaccination among some populations. As many in the field acknowledge, the scale of resistance is impacting the effectiveness of national programmes to achieve herd immunity as quickly as possible. Indeed, the rate of vaccination varies wildly between countries which has led to divergent strategies with different combinations of stick and carrot.

A key point is that compulsory vaccination is not new, and neither is hesitancy or resistance. Some US hospitals had already mandated that workers be vaccinated against influenza for some time, while Italy had made vaccination against 12 diseases, including measles, tetanus and rubella, compulsory for children up to 6 years for acceptance into nursery schools. Italy even imposes strict sanctions for violations, with loss of parental custody threatened for repeat offenders. Australia in 2016 introduced its controversial "no jab, no pay", policy under which parents of unvaccinated children lose government benefits and welfare rebates.

In some cases, these earlier controversies have inflamed the debate over COVID-19 vaccination passports and compulsion. In Italy, opinion has polarized over the government's decision to introduce its "Green Pass" on August 6, 2021, required for entry to indoor restaurants, gyms and theatres or attending events such as conferences and sporting contests. These passes, which show that individuals have received at least one vaccine dose, tested negative for COVID-19 within the past 48 h, or possess natural immunity to the virus, are decried as medical apartheid by libertarian opponents.

France has been in a similar position over its Pass Sanitaire, which became a legal requirement in August 9 for dining out, visiting a bar or hospital for non-emergencies, and travelling on long-distance trains. As in Italy, this provoked mass demonstrations led in some cases by Gilets Jeunes (yellow vest) protesters, with growing levels of radicalization. Such demonstrations were fuelled in part by the government's heavy-handed diktat that around 1.5 million health workers would be suspended without pay if they refused to be vaccinated by mid-September.

In Germany, the government has been divided over compulsory vaccination. Although Chancellor Angela Merkel's Chief of Staff Helge Braun suggested in July 2021 that those refusing vaccines should not expect the same freedoms as those who have been fully vaccinated, the country has so far edged towards incentives rather than coercion. Offers of free Bratwurst sausage with an inoculation or staging vaccination parties at nightclubs in Berlin were both popular and successful, but it is unclear whether these make a major contribution to overcoming vaccine hesitancy.

The USA meanwhile has been leaning towards a combination of stick and carrot. On the compulsion side, US President Joseph Biden required federal workers to prove their vaccination status or else endure rigorous safety protocols. Many universities and colleges have made full vaccination mandatory for students to live and study on campus in the autumn of 2021, but that drew protests and threats of non-compliance.

However, Biden sought to increase emphasis on incentives, after noting the division caused by compulsion elsewhere. Facing a renewed spike in cases late July, he called on state governments to allocate funds from his US$1.9 trillion American Rescue Plan to offer US$100 payments to people upon vaccination. Although funded centrally, it was up to the states to make the payments, with varying levels of support.

In some countries, vaccine hesitancy went almost to the top, notably in Japan despite the obvious desire to stage a successful 2020 Summer Olympic Games. The country was stymied by a historic distrust of vaccines after various earlier high-profile mistakes and misfortunes. This left a legacy of public distrust with < 30% of the population expressing confidence in vaccines or willing to have their children inoculated just before the COVID-19 pandemic began (de Figueiredo et al, 2020) . This in turn resulted in a risk averse approach to COVID-19 vaccination by the government, with the first approval for emergency use only on February 14, 2021, several months after the USA and other developed countries.

India is another major country with historical reasons for not making COVID-19 vaccination compulsory; in this case rooted in its religious, cultural and colonial history. Whatever the case, hesitancy against vaccination, not just against COVID-19 but also other diseases including polio and diphtheria, seems inspired by a combination of ignorance and mistrust of public institutions. The government is now reluctant to mandate vaccination because it believes this could be counterproductive and exacerbate societal divisions. However, hesitancy is trumped by the much greater task of scaling up production to vaccinate all those willing to receive a jab in time. India is so far way behind the target of vaccinating the whole population by the end of 2021, with only 9% fully vaccinated and 30% on one dose by mid-August 2021. There are a few countries fortunate to have low levels of vaccine hesitancy such that neither incentives nor compulsion have been necessary. One of those is Spain-in stark contrast to neighbouring France-with high vaccination rates among almost all groups, and 90% of healthcare staff and care home workers inoculated. As a result, the country has deemed measures to encourage or enforce compliance unnecessary.

More generally, while financial incentives may increase vaccination take up, they are not regarded as sustainable in the long term. Alternatively, there is scope for making vaccines themselves more appealing. Of around 100 COVID-19 vaccines currently in clinical trials, seven are delivered intranasally, which could overcome fear of injection pain as one reason for vaccination hesitancy. Increasing the appeal of vaccines could therefore provide a palatable alternative to coercion. With vaccines holding great promise against not just future pandemics but also other conditions, a major focus of social policies should therefore be on winning the argument against vaccination sceptics.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study

COVID-19 vaccine generates durable T cell memory and antibodies enhanced by preexisting cross-reactive T cell memory